SciSparc Ltd. has entered into a definitive agreement to acquire a controlling interest in Miza III Ventures Inc., a company listed on the TSX Venture Exchange. As part of the transaction, SciSparc will transfer its advanced clinical stage pharmaceutical portfolio and its approximately 51% equity stake in SciSparc Nutraceuticals Inc. to Miza. These assets are valued at about US$11.6 million. Upon closing, SciSparc will receive 4,000,000 common share purchase warrants from Miza, each exercisable at CAD 0.25 per share for five years. Additionally, SciSparc or a third party plans to provide up to CAD 1,000,000 in capital to Miza through an unsecured convertible note with a 7% annual interest rate, convertible into up to 4,000,000 common shares of Miza. The transaction is expected to close on or around October 22, 2025, subject to satisfaction of closing conditions and regulatory approval.